Axogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023

Rhea-AI Summary

Axogen, Inc. (NASDAQ: AXGN), a leader in surgical solutions for peripheral nerve injuries, announced plans to release its first quarter 2023 financial results on May 9, 2023, before market opening. Management will conduct a conference call at 8:00 a.m. ET to discuss the results, which investors can join via phone or online. Axogen specializes in technologies for nerve regeneration and repair, with a portfolio that includes products like Avance^® Nerve Graft and Axoguard Nerve Connector^®. These products are designed to restore nerve function and improve patient quality of life. Axogen's innovations are available in multiple countries, demonstrating its international reach and commitment to patient care.

Positive

• Scheduled release of Q1 2023 financial results may provide insight into company performance.
• Management's upcoming conference call could clarify business strategies and future outlook.

Negative

• None.

ALACHUA, Fla. and TAMPA, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.

Investors interested in participating in the conference call by phone may do so by dialing toll free at (866) 682-6100 or use the direct dial-in number at (862) 298-0702. Those interested in listening to the conference call live via the Internet may do so by visiting the Investors page of the company's website at www.axogeninc.com and clicking on the webcast link.

Following the conference call, a replay will be available in the Investors section of the company's website at www.axogeninc.com.

About Axogen
Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance^® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector^®, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector^®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; and Axoguard Nerve Cap^®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Contact:
Axogen, Inc.
Ed Joyce, Director, Investor Relations
ejoyce@axogeninc.com

FAQ

When will Axogen report its financial results for Q1 2023?

Axogen will report its financial results for Q1 2023 on May 9, 2023.

What time is the conference call for Axogen's Q1 2023 results?

The conference call for Axogen's Q1 2023 results is scheduled for 8:00 a.m. ET on May 9, 2023.

How can investors participate in Axogen's conference call?

Investors can participate by dialing (866) 682-6100 or (862) 298-0702, or they can join via the webcast on Axogen's website.

What products does Axogen offer for peripheral nerve repair?

Axogen offers several products, including Avance^® Nerve Graft and Axoguard Nerve Connector^®, designed to aid in peripheral nerve regeneration.

In which countries is Axogen's portfolio available?

Axogen's products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and other countries.